Wir sind mit live! Mehr erfahren
64,00 USD
-2,68
4,02 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
62,50
-1,50
2,34 %
1 Tag
-4,02 %
5 Tage
1,14 %
1 Monat
19,51 %
3 Monate
58,65 %
6 Monate
185,46 %
Seit Jahresbeginn
234,38 %
1 Jahr
326,95 %
5 Jahre
-9,83 %
10 Jahre
1.562,34 %
 

Profil: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Mitarbeiter: 765

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 47,6 %
Neutral 42,9 %
Negativ 9,5 %
Neutral
Business Wire
gestern
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Positiv
Zacks Investment Research
vor 21 Tagen
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Negativ
Benzinga
vor 23 Tagen
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
Positiv
Zacks Investment Research
vor 23 Tagen
5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential
Five stocks stand out for high efficiency, with strong receivables, asset, inventory and operating margin metrics.
5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential
Positiv
Zacks Investment Research
letzten Monat
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
Neutral
Zacks Investment Research
letzten Monat
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
Negativ
Zacks Investment Research
letzten Monat
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Positiv
Zacks Investment Research
letzten Monat
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Neutral
Zacks Investment Research
letzten Monat
Zacks Industry Outlook CareDx, BrightSpring and PACS
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
Zacks Industry Outlook CareDx, BrightSpring and PACS
Positiv
Zacks Investment Research
letzten Monat
3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage
CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage
Kursdiagramme mit Lightweight Charts™ umgesetzt